SNPX
- Synaptogenix, Inc.
()
Overview
Company Summary
Synaptogenix, Inc. (SNPX) is a company that specializes in the development and commercialization of innovative therapeutics for the treatment of neurological disorders. They focus primarily on finding solutions for Alzheimer's disease, which is a progressive neurodegenerative disorder that affects memory, thinking, and behavior.
Synaptogenix utilizes a unique approach to combat this challenging disease, known as the RG3 peptide technology. The RG3 peptide is a small protein fragment derived from a neurotrophic factor called small molecule mimetic. This technology has shown potential in promoting the growth and protection of neurons, which are the key cells involved in transmitting information in the brain.
The company's primary drug candidate, called Bryostatin-1, is being developed as a potential treatment for Alzheimer's disease. Bryostatin-1 has shown promise in preclinical and clinical studies by enhancing synaptic function, which involves the communication between neurons. By improving synaptic function, the drug aims to preserve and ultimately enhance cognitive abilities in patients suffering from Alzheimer's disease.
Apart from their drug development efforts, Synaptogenix also engages in research collaborations and strategic partnerships to advance their scientific understanding and expand their therapeutic portfolio.
In summary, Synaptogenix, Inc. focuses on developing therapeutics that utilize their proprietary RG3 peptide technology to address the neurological challenges associated with Alzheimer's disease. Their ultimate goal is to improve the lives of patients by finding innovative approaches to combat this devastating disorder.